EUVIMEDOpdag EUVIMED
Open access

Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database

Mitchell S Wachtel, Yan Zhang, Tom Xu, Maurizio Chiriva-Internati, Eldo E Frezza

Clinical medicine. Pathology · 2008-01 · 1

DOI: 10.4137/cpath.s500 ↗

At a glance

Journal article in Clinical medicine. Pathology, published online on 2008-03-19. Written by Mitchell S Wachtel and 4 co-authors. Institution: Department of Pathology. Cited 36 times so far (Crossref); 16 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

Combined hepatocellular cholangiocarcinoma (combined tumor) has been described as either a variant of hepatoma or a variant of cholangiocarcinoma. Prior studies evaluated fewer than 50 patients with combined tumors, precluding multivariate analyses. Posited was the notion that analysis of a large database would yield more definite answers.

Methods

This study used SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) to analyze 282 combined tumors, 2,035 intrahepatic cholangiocarcinomas, and 19,336 hepatomas between the years 1973-2003. Multinomial logit regression calculated point estimates and 95% confidence intervals (c.i.) for relative risk (rr). Cox regression calculated point estimates and 95% confidence intervals (c.i.) for hazard ratios (ĥ).

Results

Men less often had cholangiocarcinomas than they had combined tumors (rr = 0.63, c.i. = 0.49-0.81). Hepatomas less often than combined tumors presented with distant spread (rr = 0.56, c.i. = 0.43-0.72). Men (rr = 1.50, c.i. = 1.17-1.93) and patients with a known Asian or Pacific birthplace (rr = 2.36, c.i. = 1.56-3.56) more often had hepatomas than they had combined tumors. Among patients not known to have an Asian/Pacific birthplace, a diagnosis of cholangiocarcinoma (ĥ = 0.72, c.i. = 0.63-0.82) or hepatoma (ĥ = 0.75, c.i. = 0.66-0.86) provided a better prognosis than did a diagnosis of combined tumor.

Conclusion

Combined tumors differ from hepatomas and cholangiocarcinomas in terms of distribution and survival patterns in the population; they should be considered neither cholangiocarcinomas nor hepatomas.

Subjects

Author keywords

cholangiocarcinomacombined hepatocellular cholangiocarcinomahepatomamultinomial logitsurvival analysis

Authors and institutions

  • Department of Pathology.

Cite

APA

Wachtel, M. S., Zhang, Y., Xu, T., Chiriva-Internati, M., & Frezza, E. E. (2008). Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database. Clinical medicine. Pathology, 1. https://doi.org/10.4137/cpath.s500

Vancouver

Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE. Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database. Clinical medicine. Pathology. 2008;1. doi:10.4137/cpath.s500

BibTeX
@article{Wachtel2008,
  author = {Wachtel, Mitchell S and Zhang, Yan and Xu, Tom and Chiriva-Internati, Maurizio and Frezza, Eldo E},
  title = {Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database},
  journal = {Clinical medicine. Pathology},
  year = {2008},
  volume = {1},
  doi = {10.4137/cpath.s500}
}
Start for free →